Physician profile
Peter-Brian Andersson
NPI 1326063843
$97,440.48
in general payments reported to CMS, 2019-2025
76 companies · $9,734 in 2025
The $9,734 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $12K · 2021: $22K · 2022: $24K · 2023: $18K · 2024: $9,207 · 2025: $9,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $12K · Consulting Fee: $2,272 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,312.50 |
| Food and Beverage | $12,203.43 |
| Consulting Fee | $2,272.00 |
| Education | $134.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,198.47 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $25,399.06 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Biohaven Pharmaceuticals, INC. | $11,781.26 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $4,069.15 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $1,408.86 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $1,340.10 | 2019-2025 | Vumerity, Leqembi |
| Novartis Pharmaceuticals Corporation | $1,294.82 | 2019-2025 | |
| Amgen INC. | $865.06 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $825.00 | 2019-2025 | Nuplazid |
| Pfizer INC. | $787.96 | 2023-2025 | |
| Mdd US Operations, LLC | $768.50 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Sk Life Science, INC. | $732.39 | 2020-2025 | |
| Eisai INC. | $702.12 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $589.36 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $510.03 | 2020-2024 | Briviact |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $456.84 | 2021-2025 | Vyepti, Rexulti |
| Merz Pharmaceuticals, LLC | $426.08 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Kyowa Kirin, INC. | $418.35 | 2019-2025 | Nourianz |
| Argenx US, INC. | $387.80 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Axsome Therapeutics, INC. | $371.75 | 2023-2025 | Symbravo, Sunosi |
| Otsuka America Pharmaceutical, INC. | $361.72 | 2023-2025 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $350.71 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $348.19 | 2020-2025 | Rytary, Crexont |
| Genentech USA, INC. | $333.68 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $327.73 | 2019-2025 | Ultomiris, Soliris |
| Alnylam Pharmaceuticals INC. | $326.78 | 2019-2025 | Onpattro, Amvuttra |
| Emd Serono, INC. | $294.26 | 2019-2025 | Mavenclad |
| Sumitomo Pharma America, INC. | $278.89 | 2023-2024 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $263.10 | 2020-2025 | Trintellix |
| Celgene Corporation | $247.97 | 2022-2025 | Zeposia |
| Acorda Therapeutics, INC | $210.22 | 2022-2024 | Ampyra, Inbrija |
| Biohaven Pharmaceutical Holding Company Ltd. | $203.63 | 2022 | |
| Harmony Biosciences LLC | $199.90 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $182.90 | 2021-2025 | |
| Adamas Pharmaceuticals, INC. | $175.90 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $170.76 | 2023-2025 | Horizant, Horizant |
| Catalyst Pharmaceuticals, INC. | $163.88 | 2022-2025 | Fycompa |
| Tg Therapeutics, INC. | $157.63 | 2024-2025 | |
| Assertio Therapeutics, INC. | $138.27 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $137.67 | 2019-2021 | |
| Genzyme Corporation | $123.95 | 2019-2022 | |
| Neurelis, INC. | $123.84 | 2021-2025 | Valtoco |
| Banner Life Sciences, LLC | $122.11 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $114.39 | 2019-2025 | Qelbree |
| Nevro Corp. | $112.97 | 2023 | Senza |
| Forte Bio-Pharma LLC | $110.39 | 2025 | Tanlor |
| Abbott Laboratories | $101.45 | 2020-2025 | Infinity |
| Upsher-Smith Laboratories LLC | $99.49 | 2020-2022 | |
| Tanabe Pharma America, INC. | $96.03 | 2019-2023 | |
| Cycle Pharmaceuticals INC | $93.63 | 2025 | Bafiertam, Tascenso Odt |
| Tonix Medicines, INC. | $82.64 | 2025 | Zembrace Symtouch |
| Octapharma USA, INC. | $81.73 | 2022-2023 | Panzyga |
| Csl Behring | $77.04 | 2020-2021 | |
| Zyla Life Sciences, INC. | $76.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $76.02 | 2021-2025 | Wainua |
| Allergan, INC. | $71.94 | 2020 | |
| Horizon Therapeutics Plc | $68.97 | 2022-2023 | Uplizna |
| Vanda Pharmaceuticals INC. | $64.11 | 2024-2025 | Ponvory |
| Merz North America, INC. | $60.27 | 2019-2020 | |
| Genentech, INC. | $56.32 | 2024-2025 | Ocrevus |
| Promius Pharma LLC | $48.60 | 2019 | |
| Bausch Health US, LLC | $44.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.53 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $34.30 | 2022 | |
| Ani Pharmaceuticals, INC. | $31.03 | 2024 | Purified Cortrophin Gel |
| Cadwell Industries, INC | $27.66 | 2024 | |
| Grifols USA, LLC | $25.80 | 2025 | Gamunex-C |
| Ge Healthcare | $24.49 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 2021 | |
| Insightec,INC | $20.91 | 2024 | Exablate |
| Boston Scientific Corporation | $20.49 | 2019 | |
| Tersera Therapeutics LLC | $20.21 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.85 | 2020 | |
| Cala Health, INC. | $16.77 | 2023 | Cala Trio |
| Collegium Pharmaceutical, INC. | $13.93 | 2022 | |
| Angiodynamics, INC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter-Brian Andersson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.